TY - THES A1 - El-Mesery, Mohamed T1 - Development of CD40-targeted bifunctional scFv-TRAIL fusion proteins that induce TRAILR1- and TRAILR2-specifc cell death and dendritic cells activation T1 - Entwicklung CD40 gerichteter bifunktioneller scFv-TRAIL Fusionsproteine die TRAILR1- und TRAILR2-spezifischen Zelltod und dendritischen Zellaktivierung induzieren N2 - TRAIL is a member of TNF superfamily and mediates apoptosis by binding to two DRs, TRAILR1 and TRAILR2. Despite the fact that there are other TRAILRs, TRAILR1 and TRAILR2 receive the major research interest due to their ability to trigger apoptosis and their possible use as targets in tumor therapy. Due to the potential advantages of TRAILR1- or TRAILR2-specific targeting, we investigated recently published TRAIL DR-specific mutants, one conferring specificity for TRAILR1 (TRAILmutR1) and one for TRAILR2 (TRAILmutR2). It was well proved in this work that TRAILmutR1 shows specific binding to TRAILR1 and no specific binding to TRAILR2. TRAILmutR2 vice versa shows specific binding to TRAILR2 and no significant binding to TRAILR1. Moreover, these mutants were able to induce caspase activation and cell death in a TRAILR1/2-specific manner. Moreover, the enhancement of TRAILR2-induced apoptosis by secondary oligomerization of soluble wild-type TRAIL was confirmed for the TRAILR2-specifc TRAIL mutant and similar findings were made with the TRAILR1-specific TRAIL mutant. The soluble form of TRAIL exhibits weak apoptotic activity as compared to transmembrane TRAIL. Therefore, there is the challenge in clinical research to improve the activity of soluble TRAIL. A second strategy besides the above mentioned oligomerization to improve soluble TRAIL activity is anchoring of the molecule to the cell surface, e.g. through the genetic fusion with a scFv domain recognizing a cell surface antigen. In this work, we generated fusion proteins of TRAIL, TRAILmutR1 and TRAILmutR2 with a scFv recognizing CD40 (scFv:G28). Initially, we analyzed the functionality of both the TRAIL domain and the scFv:G28 domain of the corresponding fusion proteins. TRAIL functionality was well proved through its ability to induce cell death in TRAIL sensitive cells such as Jurkat cells, provided that scFv:G28-TRAIL fusion proteins were oligomerized by anti-Flag mAb M2. Concerning the scFv:G28 domain, the fusion proteins showed enhanced binding affinity to cell lines expressing CD40 as compared to their parental CD40-negative cells. Consistent with previous studies investigating TRAIL fusion proteins with other cell surface antigen-targeting scFvs, the scFv:G28 fusion proteins with TRAIL, TRAILmutR1 and TRAILmutR2 showed enhanced induction of cell death in a CD40-dependent manner. Moreover, our results revealed that these fusion proteins have a significant paracrine apoptotic effect on CD40-negative bystander cells upon anchoring to CD40-positive cells which are TRAIL resistant. Thus, the current work provides for the first time scFv fusion proteins of TRAIL and TRAILR1- and TRAILR2-specific TRAIL mutants with CD40-restricted activity. These fusion proteins provide the advantage of attenuating the off-target effects and the potential side effects of per se highly active TRAIL variants on one hand due to the CD40-binding dependent enhancement of activity and on the other hand due to the differential use of TRAILR1 and TRAILR2. CD40 represents a tumor associated marker which is expressed on many tumor cells but also on immune cells. Therefore, the last part of this work focused on the analysis of the ability of scFv:G28-TRAIL fusion proteins to induce CD40 signaling both in tumor cells and also in immune cells. It turned out that the scFv:G28-TRAIL fusion proteins are able to induce CD40 signaling in CD40-positive tumor cells but especially also in immune cells such as iDCs leading to their maturation and further activation of immune responses. Taken together, this work provides novel bifunctional scFv-TRAIL fusion proteins which combine the induction of apoptosis via TRAIL DR with stimulation of CD40 signaling which possibly enhances antitumor immunity. N2 - TRAIL ist ein Mitglied der TNF-Superfamilie und vermittelt Apoptose durch die Aktivierung der Todesrezeptoren, TRAILR1 und TRAILR2. Obwohl es weitere TRAIL-Rezeptoren gibt, liegt das Hauptaugenmerk auf den beiden Apoptose induzierenden Rezeptoren TRAILR1 und TRAILR2 auf Grund ihrer möglichen Anwendung in der Tumortherapie. Wegen der möglichen Vorteile eines spezifischen TRAILR1- und TRAILR2-Targetings, haben wir kürzlich publizierte TRAIL-Todesrezeptor spezifische TRAIL Mutanten untersucht, von denen eine spezifisch für TRAILR1 (TRAILmutR1) und die andere spezifisch für TRAILR2 (TRAILmutR2) ist. Es konnte in dieser Arbeit sehr gut belegt werden, dass TRAILmutR1 spezifisch an TRAILR1 bindet und keine Bindung an TRAILR2 zeigte. Dem entsprechend zeigte die Variante TRAILmutR2 nur eine spezifische Bindung an TRAILR2 und keine signifikante Bindung an TRAILR1. Des Weiteren waren die Mutanten in der Lage, die Caspase-Aktivierung und den Zelltod TRAILR1/2-abhängig zu induzieren. Außerdem konnte eine Erhöhung der TRAILR2-induzierten Apoptose durch eine sekundäre Oligomerisierung der TRAILR2-spezifische TRAIL-Mutante erzielt werden. Ähnliche Ergebnisse zeigte die TRAILR1-spezifische TRAIL-Mutante. Um die Aktivität des löslichen TRAIL Oligomerisierung unabhängig zu erhöhen, wurden in dieser Arbeit TRAIL-Fusionsproteine mit einem scFv (scFv:G28), der CD40 erkennt generiert. In Übereinstimmung mit früheren Studien, die mit TRAIL-Fusionsproteinen von anderen Zelloberflächenantigen-spezifischen scFvs wurden, zeigten die CD40-spezifischen scFv:G28 Fusionsproteine mit TRAIL, TRAILmutR1 und TRAILmutR2 eine verstärkte CD40-abhängige Induktion des Zelltods. Darüber hinaus zeigten unsere Ergebnisse, dass diese Fusionsproteine nach Bindung an CD40-positive Zellen einen parakrinen apoptotischen Effekt, auf umliegende CD40-negative Zellen haben. Diese Arbeit beschreibt somit zum ersten Mal scFv-TRAIL Fusionsproteine mit einer CD40-abhängigen TRAILR1- und TRAILR2-spezifischen Aktivität. CD40 repräsentiert einen tumorassoziierten Marker, der in vielen Tumorzellen aber auch in Zellen des Immunsystems exprimiert wird. Aus diesem Grund fokussierte sich der zweite Teil dieser Arbeit auf die Analyse der Fähigkeit der scFv:G28-TRAIL Fusionsproteine, CD40-Signaling sowohl in Tumor- als auch in Immunzellen zu stimulieren. Es konnte festgestellt werden, dass die scFv:G28-TRAIL Fusionsproteine in der Lage sind, CD40-Signaling in CD40-positiven Tumorzellen, aber auch in Immunzellen, z.B. in iDCs, in denen die ScFv-TRAIL Fusionsproteine die Reifung und Aktivierung induzieren ohne Zelltod auszulösen. Zusammengefasst beschreibt diese Arbeit neue bifunktionelle scFv-TRAIL Fusionsproteine, die die Induktion der Apoptose via TRAIL-Todesrezeptoren und die Stimulation des kostimulatorischen CD40-Moleküls kombinieren, was zu einer synergistischen dualen Antitumor-Aktivität führen kann. KW - Tumor-Nekrose-Faktor KW - Antigen CD40 KW - CD40-targeted bifunctional scFv-TRAIL fusion proteins KW - development KW - TRAIL mutants KW - CD40 gerichteter bifunktioneller scFv-TRAIL Fusionsproteine KW - Entwicklung Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-100114 ER - TY - JOUR A1 - Lagler, Charlotte A1 - El-Mesery, Mohamed A1 - Kübler, Alexander Christian A1 - Müller-Richter, Urs Dietmar Achim A1 - Stühmer, Thorsten A1 - Nickel, Joachim A1 - Müller, Thomas Dieter A1 - Wajant, Harald A1 - Seher, Axel T1 - The anti-myeloma activity of bone morphogenetic protein 2 predominantly relies on the induction of growth arrest and is apoptosis-independent JF - PLoS ONE N2 - Multiple myeloma (MM), a malignancy of the bone marrow, is characterized by a pathological increase in antibody-producing plasma cells and an increase in immunoglobulins (plasmacytosis). In recent years, bone morphogenetic proteins (BMPs) have been reported to be activators of apoptotic cell death in neoplastic B cells in MM. Here, we use bone morphogenetic protein 2 (BMP2) to show that the "apoptotic" effect of BMPs on human neoplastic B cells is dominated by anti-proliferative activities and cell cycle arrest and is apoptosis-independent. The anti-proliferative effect of BMP2 was analysed in the human cell lines KMS12-BM and L363 using WST-1 and a Coulter counter and was confirmed using CytoTox assays with established inhibitors of programmed cell death (zVAD-fmk and necrostatin-1). Furthermore, apoptotic activity was compared in both cell lines employing western blot analysis for caspase 3 and 8 in cells treated with BMP2 and FasL. Additionally, expression profiles of marker genes of different cell death pathways were analysed in both cell lines after stimulation with BMP2 for 48h using an RT-PCR-based array. In our experiments we observed that there was rather no reduction in absolute cell number, but cells stopped proliferating following treatment with BMP2 instead. The time frame (48–72 h) after BMP2 treatment at which a reduction in cell number is detectable is too long to indicate a directly BMP2-triggered apoptosis. Moreover, in comparison to robust apoptosis induced by the approved apoptotic factor FasL, BMP2 only marginally induced cell death. Consistently, neither the known inhibitor of apoptotic cell death zVAD-fmk nor the necroptosis inhibitor necrostatin-1 was able to rescue myeloma cell growth in the presence of BMP2. KW - apoptosis KW - gene expression KW - necrotic cell death KW - multiple myeloma KW - cell metabolism KW - cell cycle and cell division KW - B cells Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-158993 VL - 12 IS - 10 ER - TY - JOUR A1 - Scheurer, Mario Joachim Johannes A1 - Brands, Roman Camillus A1 - El-Mesery, Mohamed A1 - Hartmann, Stefan A1 - Müller-Richter, Urs Dietmar Achim A1 - Kübler, Alexander Christian A1 - Seher, Axel T1 - The selection of NFκB inhibitors to block inflammation and induce sensitisation to FasL-induced apoptosis in HNSCC cell lines is critical for their use as a prospective cancer therapy JF - International Journal of Molecular Science N2 - Inflammation is a central aspect of tumour biology and can contribute significantly to both the origination and progression of tumours. The NFκB pathway is one of the most important signal transduction pathways in inflammation and is, therefore, an excellent target for cancer therapy. In this work, we examined the influence of four NFκB inhibitors — Cortisol, MLN4924, QNZ and TPCA1 — on proliferation, inflammation and sensitisation to apoptosis mediated by the death ligand FasL in the HNSCC cell lines PCI1, PCI9, PCI13, PCI52 and SCC25 and in the human dermal keratinocyte cell line HaCaT. We found that the selection of the inhibitor is critical to ensure that cells do not respond by inducing counteracting activities in the context of cancer therapy, e.g., the extreme IL-8 induction mediated by MLN4924 or FasL resistance mediated by Cortisol. However, TPCA1 was qualified by this in vitro study as an excellent therapeutic mediator in HNSCC by four positive qualities: (1) proliferation was inhibited at low μM-range concentrations; (2) TNFα-induced IL-8 secretion was blocked; (3) HNSCC cells were sensitized to TNFα-induced cell death; and (4) FasL-mediated apoptosis was not disrupted. KW - HNSCC KW - NFκB KW - inhibitor KW - TPCA1 KW - apoptosis KW - inflammation KW - TNFα KW - FasL Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201524 SN - 1422-0067 VL - 20 IS - 6 ER - TY - JOUR A1 - El-Hawary, Seham S. A1 - Sayed, Ahmed M. A1 - Mohammed, Rabab A1 - Hassan, Hossam M. A1 - Rateb, Mostafa E. A1 - Amin, Elham A1 - Mohammed, Tarek A. A1 - El-Mesery, Mohamed A1 - Bin Muhsinah, Abdullatif A1 - Alsayari, Abdulrhman A1 - Wajant, Harald A1 - Anany, Mohamed A. A1 - Abdelmohsen, Usama Ramadan T1 - Bioactive brominated oxindole alkaloids from the Red Sea sponge Callyspongia siphonella JF - Marine Drugs N2 - In the present study, LC-HRESIMS-assisted dereplication along with bioactivity-guided isolation led to targeting two brominated oxindole alkaloids (compounds 1 and 2) which probably play a key role in the previously reported antibacterial, antibiofilm, and cytotoxicity of Callyspongia siphonella crude extracts. Both metabolites showed potent antibacterial activity against Gram-positive bacteria, Staphylococcus aureus (minimum inhibitory concentration (MIC) = 8 and 4 µg/mL) and Bacillus subtilis (MIC = 16 and 4 µg/mL), respectively. Furthermore, they displayed moderate biofilm inhibitory activity in Pseudomonas aeruginosa (49.32% and 41.76% inhibition, respectively), and moderate in vitro antitrypanosomal activity (13.47 and 10.27 µM, respectively). In addition, they revealed a strong cytotoxic effect toward different human cancer cell lines, supposedly through induction of necrosis. This study sheds light on the possible role of these metabolites (compounds 1 and 2) in keeping fouling organisms away from the sponge outer surface, and the possible applications of these defensive molecules in the development of new anti-infective agents. KW - Callyspongia siphonella KW - LC-HRESIMS KW - metabolomic profiling KW - oxindole alkaloids KW - tisindoline KW - antibacterial KW - antibiofilm KW - antitrypanosomal KW - anticancer Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201485 VL - 17 IS - 8 ER - TY - JOUR A1 - Schmitz, Werner A1 - Koderer, Corinna A1 - El-Mesery, Mohamed A1 - Gobik, Sebastian A1 - Sampers, Rene A1 - Straub, Anton A1 - Kübler, Alexander Christian A1 - Seher, Axel T1 - Metabolic fingerprinting of murine L929 fibroblasts as a cell-based tumour suppressor model system for methionine restriction JF - International Journal of Molecular Sciences N2 - Since Otto Warburg reported in 1924 that cancer cells address their increased energy requirement through a massive intake of glucose, the cellular energy level has offered a therapeutic anticancer strategy. Methionine restriction (MetR) is one of the most effective approaches for inducing low-energy metabolism (LEM) due to the central position in metabolism of this amino acid. However, no simple in vitro system for the rapid analysis of MetR is currently available, and this study establishes the murine cell line L929 as such a model system. L929 cells react rapidly and efficiently to MetR, and the analysis of more than 150 different metabolites belonging to different classes (amino acids, urea and tricarboxylic acid cycle (TCA) cycles, carbohydrates, etc.) by liquid chromatography/mass spectrometry (LC/MS) defines a metabolic fingerprint and enables the identification of specific metabolites representing normal or MetR conditions. The system facilitates the rapid and efficient testing of potential cancer therapeutic metabolic targets. To date, MS studies of MetR have been performed using organisms and yeast, and the current LC/MS analysis of the intra- and extracellular metabolites in the murine cell line L929 over a period of 5 days thus provides new insights into the effects of MetR at the cellular metabolic level. KW - methionine restriction KW - caloric restriction KW - mass spectrometry KW - LC/MS KW - liquid chromatography/mass spectrometry KW - metabolism KW - L929 KW - amino acid Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-259198 SN - 1422-0067 VL - 22 IS - 6 ER - TY - JOUR A1 - Schmitz, Werner A1 - Ries, Elena A1 - Koderer, Corinna A1 - Völter, Maximilian Friedrich A1 - Wünsch, Anna Chiara A1 - El-Mesery, Mohamed A1 - Frackmann, Kyra A1 - Kübler, Alexander Christian A1 - Linz, Christian A1 - Seher, Axel T1 - Cysteine restriction in murine L929 fibroblasts as an alternative strategy to methionine restriction in cancer therapy JF - International Journal of Molecular Sciences N2 - Methionine restriction (MetR) is an efficient method of amino acid restriction (AR) in cells and organisms that induces low energy metabolism (LEM) similar to caloric restriction (CR). The implementation of MetR as a therapy for cancer or other diseases is not simple since the elimination of a single amino acid in the diet is difficult. However, the in vivo turnover rate of cysteine is usually higher than the rate of intake through food. For this reason, every cell can enzymatically synthesize cysteine from methionine, which enables the use of specific enzymatic inhibitors. In this work, we analysed the potential of cysteine restriction (CysR) in the murine cell line L929. This study determined metabolic fingerprints using mass spectrometry (LC/MS). The profiles were compared with profiles created in an earlier work under MetR. The study was supplemented by proliferation studies using D-amino acid analogues and inhibitors of intracellular cysteine synthesis. CysR showed a proliferation inhibition potential comparable to that of MetR. However, the metabolic footprints differed significantly and showed that CysR does not induce classic LEM at the metabolic level. Nevertheless, CysR offers great potential as an alternative for decisive interventions in general and tumour metabolism at the metabolic level. KW - methionine restriction KW - cysteine restriction KW - mass spectrometry KW - LC/MS KW - cancer therapy KW - caloric restriction KW - homocysteine KW - amino acid analogues KW - cysteine synthase inhibitor Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-265486 SN - 1422-0067 VL - 22 IS - 21 ER - TY - JOUR A1 - Koderer, Corinna A1 - Schmitz, Werner A1 - Wünsch, Anna Chiara A1 - Balint, Julia A1 - El-Mesery, Mohamed A1 - Volland, Julian Manuel A1 - Hartmann, Stefan A1 - Linz, Christian A1 - Kübler, Alexander Christian A1 - Seher, Axel T1 - Low energy status under methionine restriction is essentially independent of proliferation or cell contact inhibition JF - Cells N2 - Nonlimited proliferation is one of the most striking features of neoplastic cells. The basis of cell division is the sufficient presence of mass (amino acids) and energy (ATP and NADH). A sophisticated intracellular network permanently measures the mass and energy levels. Thus, in vivo restrictions in the form of amino acid, protein, or caloric restrictions strongly affect absolute lifespan and age-associated diseases such as cancer. The induction of permanent low energy metabolism (LEM) is essential in this process. The murine cell line L929 responds to methionine restriction (MetR) for a short time period with LEM at the metabolic level defined by a characteristic fingerprint consisting of the molecules acetoacetate, creatine, spermidine, GSSG, UDP-glucose, pantothenate, and ATP. Here, we used mass spectrometry (LC/MS) to investigate the influence of proliferation and contact inhibition on the energy status of cells. Interestingly, the energy status was essentially independent of proliferation or contact inhibition. LC/MS analyses showed that in full medium, the cells maintain active and energetic metabolism for optional proliferation. In contrast, MetR induced LEM independently of proliferation or contact inhibition. These results are important for cell behaviour under MetR and for the optional application of restrictions in cancer therapy. KW - methionine restriction KW - caloric restriction KW - mass spectrometry KW - LC/MS KW - liquid chromatography/mass spectrometry KW - metabolomics KW - L929 KW - amino acid KW - proliferation KW - contact inhibition Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262329 SN - 2073-4409 VL - 11 IS - 3 ER - TY - JOUR A1 - Volland, Julian Manuel A1 - Kaupp, Johannes A1 - Schmitz, Werner A1 - Wünsch, Anna Chiara A1 - Balint, Julia A1 - Möllmann, Marc A1 - El-Mesery, Mohamed A1 - Frackmann, Kyra A1 - Peter, Leslie A1 - Hartmann, Stefan A1 - Kübler, Alexander Christian A1 - Seher, Axel T1 - Mass spectrometric metabolic fingerprinting of 2-Deoxy-D-Glucose (2-DG)-induced inhibition of glycolysis and comparative analysis of methionine restriction versus glucose restriction under perfusion culture in the murine L929 model system JF - International Journal of Molecular Sciences N2 - All forms of restriction, from caloric to amino acid to glucose restriction, have been established in recent years as therapeutic options for various diseases, including cancer. However, usually there is no direct comparison between the different restriction forms. Additionally, many cell culture experiments take place under static conditions. In this work, we used a closed perfusion culture in murine L929 cells over a period of 7 days to compare methionine restriction (MetR) and glucose restriction (LowCarb) in the same system and analysed the metabolome by liquid chromatography mass spectrometry (LC-MS). In addition, we analysed the inhibition of glycolysis by 2-deoxy-D-glucose (2-DG) over a period of 72 h. 2-DG induced very fast a low-energy situation by a reduced glycolysis metabolite flow rate resulting in pyruvate, lactate, and ATP depletion. Under perfusion culture, both MetR and LowCarb were established on the metabolic level. Interestingly, over the period of 7 days, the metabolome of MetR and LowCarb showed more similarities than differences. This leads to the conclusion that the conditioned medium, in addition to the different restriction forms, substantially reprogramm the cells on the metabolic level. KW - amino acid restriction KW - glucose restriction KW - mass spectrometry KW - low carb KW - 2-deoxy-D-glucose KW - 2-DG KW - methionine KW - perfusion culture KW - energy restriction KW - caloric restriction Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-286007 SN - 1422-0067 VL - 23 IS - 16 ER - TY - JOUR A1 - Wünsch, Anna Chiara A1 - Ries, Elena A1 - Heinzelmann, Sina A1 - Frabschka, Andrea A1 - Wagner, Peter Christoph A1 - Rauch, Theresa A1 - Koderer, Corinna A1 - El-Mesery, Mohamed A1 - Volland, Julian Manuel A1 - Kübler, Alexander Christian A1 - Hartmann, Stefan A1 - Seher, Axel T1 - Metabolic silencing via methionine-based amino acid restriction in head and neck cancer JF - Current Issues in Molecular Biology N2 - In recent years, various forms of caloric restriction (CR) and amino acid or protein restriction (AAR or PR) have shown not only success in preventing age-associated diseases, such as type II diabetes and cardiovascular diseases, but also potential for cancer therapy. These strategies not only reprogram metabolism to low-energy metabolism (LEM), which is disadvantageous for neoplastic cells, but also significantly inhibit proliferation. Head and neck squamous cell carcinoma (HNSCC) is one of the most common tumour types, with over 600,000 new cases diagnosed annually worldwide. With a 5-year survival rate of approximately 55%, the poor prognosis has not improved despite extensive research and new adjuvant therapies. Therefore, for the first time, we analysed the potential of methionine restriction (MetR) in selected HNSCC cell lines. We investigated the influence of MetR on cell proliferation and vitality, the compensation for MetR by homocysteine, the gene regulation of different amino acid transporters, and the influence of cisplatin on cell proliferation in different HNSCC cell lines. KW - amino acid restriction KW - caloric restriction KW - methionine KW - HNSCC KW - SCCHN KW - cisplatin KW - amino acid transporter KW - SLC-family KW - cell vitality KW - low energy metabolism Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-319257 SN - 1467-3045 VL - 45 IS - 6 SP - 4557 EP - 4573 ER -